YUMAB is a biotech company founded in 2012 by scientists of the Technical University of Braunschweig. Specializing in the generation and optimization of recombinant antibodies for therapy and diagnostics, YUMAB has rapidly grown to one of the world leaders in the development of fully human antibodies. The experts behind YUMAB have more than 30 years of experience in the field of recombinant antibodies by always using the latest technologies. In order to push forward innovation, YUMAB also collaborates with partners worldwide. This combination makes it possible to offer novel solutions to current and future challenges in the area of therapeutic antibodies.
© Photos: Verena Meier
info@yumab.com
WEB
www.linkedin.com/company/yumab-gmbh/
FOUNDED IN
2012
FOUNDERS
Prof. Dr. Stefan Dübel
Prof. Dr. Michael Hust
Dr. Thomas Schirrmann
Dr. André Frenzel
CEO
Dr. Thomas Schirrmann
EMPLOYEES
30
BUSINESS FIELDS
- Generation of full-human antibodies and lead development
- Antibody libraries
- Engineering & Humanization
- Professional R&D services
- Flexible entry and exit points in every project phase
- Partnered innovations
Contact
Alexander Ehm, Global Business Development
Phone +49 (0)531 481170-0
E-Mail info@yumab.com
Science Campus Braunschweig-Süd Inhoffenstr. 7 38124 Braunschweig